Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is
important in the management of these tumors, but current imaging methods have limitations in
providing the necessary information for optimal treatment of these patients. The goal of this
study is to evaluate the potential utility of positron emission tomography (PET) with
3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) in the medical management of brain tumors in
children. Funding source - FDA Office of Orphan Product Development (OOPD)